- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Investigators at the University of California, Riverside, have developed a simple and cost-effective method of building conducting polymer nanowires that can detect a wide range of levels of a cancer biomarker. This work, which was published in the journal Analytical Chemistry, could serve as a model for portable cancer detection equipment suitable for use in a doctor's office.
Ashok Mulchandani, Ph.D., led the research team that developed this new device. At its heart lies polypyrrole nanowires connected to a pair of gold electrodes spaced a mere 3 microns apart. The researchers use an applied electric field to move individual nanowires into proper alignment on the gold electrodes. They then coat the nanowires with a material known as EDC that can serve as an attachment point for antibodies and other molecules that bind to specific cancer biomarkers. In the work reported in their recent paper, the investigators attached an antibody that binds to the cancer biomarker CA 125.
When solutions with known concentrations of CA 125 were applied to the biosensor, the device accurately measured concentrations as low as 1 "enzymatic unit" per milliliter (U/mL) of solution to as high as 1,000 U/mL. The maximal normal blood level of CA 125 is considered to be 35 U/mL. The researchers obtained identical results when they tested human blood plasma for CA 125 levels.
The researchers note that their next step will be to create a device capable of measuring a panel of disease markers simultaneously. They also plan to incorporate their biosensor into a microfluidic device that would be suitable for use in a portable disease detection system.
This work is detailed in the paper "Single conducting polymer nanowire chemiresistive label-free immunosensor for cancer biomarker." An abstract of this paper is available at the journal's Web site.
View abstract here pubs.acs.org/doi/abs/10.1021/ac802319f
About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
Copyright © NCI Alliance for Nanotechnology in CancerIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015
Healthcare Nanotechnology (Nanomedicine) Market Size To 2020 June 5th, 2015
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Engineering the world’s smallest nanocrystal July 2nd, 2015
Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015